The ASAM Treatment of Opioid Use Disorder Course
The ASAM Treatment of Opioid Use Disorder Course provides eight hours of required education to qualify for the waiver to prescribe buprenorphine in an office-based setting and covers essential information for providers to identify, assess, diagnose, and manage patients with opioid use disorder (OUD). The course covers the latest information on medications and treatments for OUD. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This course is fully online and can be completed at your own pace. The flow of this online course uses a mix of didactic materials, case studies, learning activities, and assessments.
- Physicians who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
- Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.
Upon completion, you will be able to:
- Identify, assess, and diagnose patients with opioid use disorder while considering severity, chronicity, individual characteristics, and psychiatric and medical comorbidities.
- Develop an individualized, patient-centered treatment plan, including negotiating treatment goals by evaluating appropriate medication- and psychosocial-based treatment options.
- Monitor progress and modify treatment plans based on patient needs and progress toward treatment goals.
- Implement best practices for office systems, including team-based care, to support treatment with medications for opioid use disorder.
- Examine misconceptions, stigma, and complexities (bioethical, social, clinical, public health) associated with opioid use disorder and the use of medications to treat opioid use disorder.
Daniel P. Alford, MD, MPH, FACP, DFASAM
Dr. Daniel Alford is a Professor of Medicine and Associate Dean of Continuing Medical Education at Boston University School of Medicine (BUSM). He is on staff in the Section of General Internal Medicine and Director of the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center. He is the Medical Director of the CDC-funded Boston Sustainable Models for unhealthy Alcohol use ReducTion (B SMART) and the HRSA funded SBIRT And FASD Education, Support and Treatment (SAFEST) Choice programs.
Dr. Daniel Alford has no relevant financial disclosures.
Debra Newman, PA-C, MPAS, MPH
Debra Newman currently serves as a treatment provider for First Judicial District Court, Adult Drug Court for Santa Fe and Rio Arriba Counties, New Mexico. She is also working part-time as a contract provider in Chemical Dependency for Kaiser Permanente in Denver, Colorado. Debra has worked in residential treatment as well as out-patient adult psychiatry and addiction medicine. She is currently working with the PA Foundation and NIDA on a grant examining the role of PAs in drug courts.
Debra Newman has no relevant financial disclosures.
Yngvild K. Olsen, MD, MPH, DFASAM
Dr. Yngvild Olsen graduated from Harvard Medical School in 1997, from the residency training program in internal medicine at Boston Medical Center in 2000, and from the Fellowship in General Internal Medicine at the Johns Hopkins School of Medicine in 2001. Dr. Olsen also serves as the Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services in Baltimore City. Dr. Olsen currently serves as Vice President of the American Society of Addiction Medicine and is a member of the Public Policy Committee. She is the Immediate Past President of the Maryland Society of Addiction Medicine, Immediate Past President of the Maryland Association for the Treatment of Opioid Dependence, and a Board member of the National Council on Alcoholism and Drug Dependence-MD (NCADD-MD).
Yngvild K. Olsen has no relevant financial disclosures.
Edwin Salsitz, MD, DFASAM
Dr. Edwin Salsitz has been an attending physician at Mt. Sinai Beth Israel, Division of Chemical Dependency, in New York City since 1983, and is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM) and the Board of Internal Medicine and Pulmonary Disease.
Dr. Edwin Salsitz has no relevant financial disclosures.
Kristin E. Smith, DNP, FNP-C
Kristin Smith graduated from St. John Fisher’s FNP/DNP program in May 2013. She is a staff clinician and the Program Director of a Nurse Practitioner (NP) Residency Program at Highland Family Medicine, where she provides Medication Assisted Treatment (MATx) in both dedicated suboxone clinics as well as integrated primary care settings. Dr. Smith is also a certified American Academy of HIV Medicine Specialist with experience providing HIV care and Pre/Post-Exposure prophylaxis. Prior to transitioning to her current role, she served as the Clinical Director of an Opioid Overdose Prevention Program, where she became passionate about harm reduction while providing community training on Naloxone, teaching safe injection practices, and providing needle exchange services in collaboration with a team of individuals through Trillium Health.
Kristin Smith has no relevant financial disclosures.
Bernard Stuetz PA-C, MA
Bernard Stuetz is the Past President of the Society of Physician Assistants in Addiction Medicine and currently acting as Chief Delegate to the American Academy of PAs (AAPA) House of Delegates (HOD). He is also the Director for Federal Affairs. He has been a delegate to the AAPA HOD for 31 years. He was a member of the AAPA Recertification Committee in 2012, during which he recommended changes to the ten-year cycle requirements. As a delegate in the AAPA HOD, he was the lead advocate to change the re-certification cycle from six to ten years. He was the first PA to work in the White House on Health Care Policy from 1993 to 1995. Having practiced Addiction Medicine for 25 years, Mr. Stuetz currently works in an OTP and Buprenorphine practice.
Bernard Stuetz has no relevant financial disclosures.
Matt Tierney, APRN
Matt Tierney is a Nurse Practitioner and a Clinical Professor at the UCSF School of Nursing. He also serves as Clinical Director of Substance Use Treatment and Education for the Office of Population Health at UCSF Health. The focus of his career has been on improving essential addiction treatment delivery locally, regionally, and nationally. He is a Fellow of the American Academy of Nursing, where he serves on the Expert Panel on Psychiatric-Mental Health and Substance Use. Matt is also President-Elect of the American Psychiatric Nurses Association and represents APNA as a sponsoring member of the National Academies of Science Engineering and Medicine's Forum of Mental Health and Substance Use Disorders. He is an ASAM member who has been teaching waiver training courses since 2008. He has treated over 1,600 patients with buprenorphine and has worked in licensed Opiate Treatment programs providing all three FDA-approved medications for OUD treatment.
Matt Tierney has no relevant financial disclosures.
Deanna Wilson, MD, MPH
Dr. Deanna Wilson is an Assistant Professor of Medicine and Pediatrics at the University of Pittsburgh School of Medicine. She received her MD from Yale University School of Medicine and trained in internal medicine and pediatrics at the Johns Hopkins University School of Medicine. She also completed additional subspecialty training in both adolescent and addiction medicine at Johns Hopkins.
Dr. Deanna Wilson has no relevant financial disclosures.
American Association of Nurse Practitioners (AANP)
This activity is approved for 8.0 contact hour(s) of continuing education (which includes 6.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21075052. This activity was planned in accordance with AANP Accreditation Standards and Policies
American Academy of Physician Assistants (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. Approval is valid from 6/10/2021 to 6/10/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-200882.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Family Physicians
The AAFP has reviewed The ASAM Treatment of Opioid Use Disorder Course and deemed it acceptable for up to 8.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 01/03/2022 to 01/03/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA / AAFP Equivalency
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification
American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.
American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.
American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
Royal College of Physicians and Surgeons of Canada (RCPSC)
Royal College Fellows can use participation in Accredited Continuing Medical Education to earn Section 3 Credits.
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships for the Planning Committees and Presenters. All activity Planning Committee members and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
- 8.00 AAFP Prescribed
- 8.00 AANP Contact Hours
- 6.75 AANP Pharmacology Contact Hours
- 8.00 AAPA Category I CME
- 8.00 AMA PRA Category 1 Credit™
This course is offered through ASAM eLearning.
To take this course you will be redirected to ASAM eLearning's website. You must login or create an account with ASAM eLearning in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch